Modulation of monoaminergic neural circuits: Potential for the treatment of type 2 diabetes mellitus

Treatments in Endocrinology

Volumn 1, Issue 2, 2002, Pages 71-78

  Pijl, Hanno ^a   Meinders, Edo A ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 5 HYDROXYTRYPTOPHAN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BROMOCRIPTINE; CLOZAPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; LEVODOPA; NORADRENALIN; OLANZAPINE; OXIDOPAMINE; RISPERIDONE;

BLOOD PRESSURE REGULATION; DOPAMINERGIC SYSTEM; DRUG EFFICACY; DRUG SAFETY; GLUCOSE METABOLISM; HUMAN; HYPERTENSION; HYPOTHALAMUS NUCLEUS; INSULIN RESISTANCE; METABOLIC DISORDER; MONOAMINE NERVE CELL; NEUROTRANSMISSION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; REVIEW; TISSUE INJURY;

ANIMALS; BIOGENIC MONOAMINES; BRAIN CHEMISTRY; DIABETES MELLITUS, TYPE 2; DOPAMINE AGENTS; HUMANS; SYMPATHOLYTICS;

EID: 0038007567     PISSN: 11756349     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024677-200201020-00001     Document Type: Review

References (90)

1. DeFronzo RA. Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988: 37: 667-87
2. Neel JV, Weder AB, Julius S. Type II diabetes, essential hypertension, and obesity as "syndromes of impaired genetic homeostasis": the "thrifty genotype" hypothesis enters the 21 st century. Perspect Biol Med 1998; 42: 44-74
3. Meier AH, Cincotta AH. Circadian rhythms regulate the expression of the thrifty genotype/phenotype. Diabetes Rev 1997; 4: 464-87
4. Leibowitz SF. Neurochemical-neuroendocrine systems in the brain controlling macronutrient intake and metabolism. Trends Neurosci 1992; 15: 491-7
5. Wellman PJ. Norepinephrine and the control of food intake. Nutrition 2000; 16: 837-42
6. Bray GA, York DA. The MONA LISA hypothesis in the time ofleptin. Recent Prog Horm Res 1998; 53: 95-117
7. Cincotta AH, Wilson JM, deSouza CJ, et al. Properly timed injections of cortisol and prolactin produce long-term reductions in obesity, hyperinsulinaemia and insulin resistance in the Syrian hamster (Mesocricetus auratus). J Endocrinol 1989: 120: 385-91
8. Spieler RE, Meier AH. Noeske TA. Temperature-induced phase shift of daily rhythm of serum prolactin in gulf killifish. Nature 1978; 271: 469-70
9. Meier AH, Fivizzani AJ. Changes in the daily rhythm of plasma corticosterone concentration related to seasonal conditions in the white-throated sparrow, Zonotrichia albicollis. Proc Soc Exp Biol Med 1975; 150: 356-62
10. Joseph MM, Meier AH. Circadian component in the fattening and reproductive responses to prolactin in the hamster. Proc Soc Exp Biol Med 1974; 146: 1150-5
11. Telegdy G, Vermes I. Effect of adrenocortical hormones on activity of the serotoninergic system in limbic structures in rats. Neuroendocrinology 1975; 18: 16-26
12. Moore KE, Demarest KT, Johnston CA. Influence of prolactin on dopaminergic neuronal systems in the hypothalamus. Fed Proc 1980; 39: 2912-6
13. Wilson JM, Meier AH. Resetting the annual cycle with timed daily injections of 5-hydroxytryptophan and L-dihydroxyphenylalanine in Syrian hamsters. Chronobiol Int 1989; 6: 113-21
14. Miller LJ, Meier AH. Circadian neurotransmitter activity resets the endogenous annual cycles in a migratory sparrow. J Interdiscipl Cycle Res 1983; 14: 85-94
15. Luo S, Meier AH Cincotta AH. Bromocriptine reduces obesity, glucose intolerance and extracellular monoamine metabolite levels in the ventromedial hypothalamus of Syrian hamsters. Neuroendocrinology 1998; 68: 1-10
16. Luo S, Luo J, Cincotta AH. Suprachiasmatic nuclei monoamine metabolism of glucose tolerant versus intolerant hamsters. Neuroreport 1999; 10: 2073-7
17. Luo S, Luo J, Meier AH, et al. Dopaminergic neurotoxin administration to the area of the suprachiasmatic nuclei induces insulin resistance. Neuroreport 1997; 8: 3495-9
18. Buijs RM, Kalsbeek A. Hypothalamic integration of central and peripheral clocks. Nat Rev Neurosci 2001: 2: 521-6
19. Luiten PG, ter Horst GJ, Steffens AB. The hypothalamus, intrinsic connections and outflow pathways to the endocrine system in relation to the control of feeding and metabolism. Prog Neurobiol 1987; 28: 1-54
20. The role of the SCN in the regulation of energy metabolism. In: Nagai K, Nakagawa H, Nagai K, et al., editors. Central regulation of energy metabolism with special reference to circadian rhtythm. Boca Raton (FL): CRC Press, 1992, 44
21. Shimazu T, Noma M, Saito M. Chronic infusion of norepinephrine into the ventromedial hypothalamus induces obesity in rats. Brain Res 1986: 369: 215-23
22. Liang Y. Luo S, Cincotta AH. Long-term infusion of norepinephrine plus serotonin into the ventromedial hypothalamus impairs pancreatic islet function. Metabolism 1999; 48: 1287-9
23. Luo S, Luo J, Cincotta AH. Chronic ventromedial hypothalamic infusion of norepinephrine and serotonin promotes insulin resistance and glucose intolerance. Neuroendocrinology 1999; 70: 460-5
24. Cincotta AH, Luo S, Zhang Y, et al. Chronic infusion of norepinephrine into the VMH of normal rats induces the obese glucose-intolerant state. Am J Physiol Regul Integr Comp Physiol 2000; 278: R435-44
25. Nonogaki K, Iguchi A. Role of central neural mechanisms in the regulation of hepatic glucose metabolism. Life Sci 1997; 60: 797-807
26. Meguid MM. Fetissov SO, Blaha V, et al. Dopamine and serotonin VMN release is related to feeding status in obese and lean Zucker rats. Neuroreport 2000: 11: 2069-72
27. Oltmans GA. Norepinephrine and dopamine levels in hypothalamic nuclei of the genetically obese mouse (ob/ob). Brain Res 1983; 273: 369-73
28. Wright BE, Svec F. Porter JR. Central effects of dehydroepiandrosterone in Zucker rats. Int J Obes Relat Metab Disord 1995; 19: 887-92
29. Levin BE, Dunn-Meynell AA. Dysregulation of arcuate nucleus preproneuropeptide Y mRNA in diet-induced obese rats. Am J Physiol 1997: 272: R1365-70
30. Jones AP, Pothos EN, Rada P, et al. Maternal hormonal manipulations in rats cause obesity and increase medial hypothalamic norepinephrine release in male offspring. Brain Res Dev Brain Res 1995: 88: 127-31
31. Garris DR. Age- and diabetes-associated alterations in regional brain norepinephrine concentrations and adrenergic receptor populations in C57BL/KsJ mice. Brain Res Dev Brain Res 1990; 51: 161-6
32. Feldman JM, Blalock JA, Zern RT. Elevated hypothalamic norepinephrine content in mice with the hereditary obese-hyperglycemic syndrome. Horm Res 1979; 11: 170-8
33. Lorden JF, Oltmans GA, Margules DL. Central catecholamine levels in genetically obese mice (obob and dbdb). Brain Res 1975; 96: 390-4
34. Oltmans GA, Lorden JF. Margules DL. Effects of food restriction and mutation on central catecholamine levels in genetically obese mice. Pharmacol Biochem Behav 1976; 5: 617-20
35. Boundy VA, Cincotta AH. Hypothalamic adrenergic receptor changes in the metabolic syndrome of genetically obese (ob/ob) mice. Am J Physiol Regul Integr Comp Physiol 2000; 279: R505-14
36. Jhanwar-Uniyal M, Awad IR, Gearhart GM, et al. Higher alpha-noradrenergic receptors in paraventricular nucleus of obese Zucker rats: decline after food deprivation. Pharmacol Biochem Behav 1991; 40: 853-9
37. Kraszewski KZ, Cincotta AH. Increased responsiveness of ventromedial hypothalamic neurons to norepinephrine in obese versus lean mice: relation to the metabolic syndrome. Int J Mol Med 2000; 5: 349-55
38. Zhou Q-Y, Palmiter RD. Dopamine deficient mice are severely hypoactive, adipsic and aphagic. Cell 1995; 83: 1197-209
39. Szczypka MS, Rainey MA. Palmiter RD. Dopamine is required for hyperphagia in Lep(ob/ob) mice. Nat Genet 2000; 25: 102-4
40. Leibowitz SF. Rossakis C. Mapping study of brain dopamine- and epinephrine-sensitive sites which cause feeding suppression in the rat. Brain Res 1979; 172: 101-13
41. Leibowitz SF. Catecholaminergic mechanisms of the lateral hypothalamus: their role in the mediation of amphetamine anorexia. Brain Res 1975; 98: 529-45
42. Cravchik A. Sibley DR, Gejman PV. Functional analysis of the human D2 dopamine receptor missense variants. J Biol Chem 1996; 271: 26013-7
43. Tataranni PA. Baier L, Jenkinson C, et al. A Ser311Cys mutation in the human dopamine receptor D2 gene is associated with reduced energy expenditure. Diabetes 2001: 50: 901-4
44. Comings DE, Flanagan SD, Dietz G. et al. The dopamine D2 receptor (DRD2) as a major gene in obesity and height. Biochem Med Metab Biol 1993; 50: 176-85
45. Jenkinson CP, Hanson R. Cray K, et al. Association of dopamine D2 receptor polymorphisms Ser311Cys and TaqIA with obesity or type 2 diabetes mellitus in Pima Indians. Int J Obes Relat Metab Disord 2000; 24: 1233-8
46. Blum K, Braverman ER, Wood RC, et al. Increased prevalence of the Taq I A1 allele of the dopamine receptor gene (DRD2) in obesity with comorbid substance use disorder: a preliminary report. Pharmacogenetics 1996; 6: 297-305
47. Comings DE, Comings BG, Muhleman D. et al. The dopamine D2 receptor locus as a modifying gene in neuropsychiatric disorders. JAMA 1991; 266: 1793-800
48. Wang GJ, Volkow ND, Logan J, et al. Brain dopamine and obesity. Lancet 2001; 357: 354-7
49. Baptista T. Body weight gain induced by antipsychotic drugs: mechanisms and management. Acta Psychiatr Scand 1999: 100: 3-16
50. Bray GA. Drug treatment of obesity. Baillieres Best Pract Res Clin Endocrinol Metab 1999; 13: 131-48
51. Di Chiara G, Porceddu ML. Vargiu L, et al. Stimulation of "regulatory" dopamine receptors by bromocriptine (CB-154). Pharmacology 1978; 16 Suppl. 1: 135-42
52. Lew JY, Hata F, Ohashi T, et al. The interactions of bromocriptine and lergotrile with dopamine and alpha-adrenergic receptors. J Neural Transm 1977; 41: 109-21
53. Maj J, Gancarczyk L. Rawlow A. The influence of bromocriptine on serotonin neurons. J Neural Transm 1977; 41: 253-64
54. Carey RM, Van Loon GR, Baines AD, et al. Suppression of basal and stimulated noradrenergic activities by the dopamine agonist bromocriptine in man. J Clin Endocrinol Metab 1983; 56: 595-602
55. Ziegler MG, Lake CR, Williams AC, et al. Bromocriptine inhibits norepinephrine release. Clin Pharmacol Ther 1979; 25: 137-42
56. Jackson DM, Mohell N, Georgiev J, et al. Time course of bromocriptine induced excitation in the rat: behavioural and biochemical studies. Naunyn Schmiedebergs Arch Pharmacol 1995: 351: 146-55
57. Ferre S, Cortes R, Artigas F. Dopaminergic regulation of the serotonergic raphestriatal pathway: microdialysis studies in freely moving rats. J Neurosci 1994; 14: 4839-46
58. Cincotta AH, Meier AH. Reductions of body fat stores and total plasma cholesterol and triglyceride concentrations in several species by bromocriptine treatment. Life Sci 1989; 45: 2247-54
59. Cincotta AH, Schiller BC, Meier AH. Bromocriptine inhibits the seasonally occurring obesity, hyperinsulinemia, insulin resistance, and impaired glucose tolerance in the Syrian hamster, Mesocricetus auratus. Metabolism 1991; 40: 639-44
60. Cincotta AH, MacEachern TA, Meier AH. Bromocriptine redirects metabolism and prevents seasonal onset of obese hyperinsulinemic state in Syrian hamsters. Am J Physiol 1993; 264: E285-93
61. Cincotta AH, Meier AH. Bromocriptine inhibits in vivo free fatty acid oxidation and hepatic glucose output in seasonally obese hamsters (Mesocricetus auratus). Metabolism 1995: 44: 1349-55
62. Luo S, Liang Y, Cincotta AH. Intracerebroventricular administration of bromocriptine ameliorates the insulin-resistant/glucose-intolerant state in hamsters. Neuroendocrinology 1999; 69: 160-6
63. Jackson DM, Ross SB, Hashizume M. Further studies on the interaction between bromocriptine and SKF38393 in reserpine and alpha methyl-para-tyrosine-treated mice. Psychopharmacology (Berl) 1988; 94: 321-7
64. Jackson DM, Hashizume M. Bromocriptine induces marked locomotor stimulation in dopamine-depleted mice when D-1 dopamine receptors are stimulated with SKF38393. Psychopharmacology (Berl) 1986; 90: 147-9
65. Zhang Y, Scislowski PW, Prevelige R, et al. Bromocriptine/SKF38393 treatment ameliorates dyslipidemia in ob/ob mice. Metabolism 1999; 48: 1033-40
66. Cincotta AH, Tozzo E, Scislowski PW. Bromocriptine/SKF38393 treatment ameliorates obesity and associated metabolic dysfunctions in obese (ob/ob) mice. Life Sci 1997; 61: 951-6
67. Liang Y, Lubkin M, Sheng H, et al. Dopamine agonist treatment ameliorates hyperglycemia, hyperlipidemia, and the elevated basal insulin release from islets of ob/ob mice. Biochim Biophys Acta 1998; 1405: 1-13
68. Liang Y, Jetton TL, Lubkin M, et al. Bromocriptine/SKF38393 ameliorates islet dysfunction in the diabetic (db/db) mouse. Cell Mol Life Sci 1998; 54: 703-11
69. Arneric SP, Chow SA, Long JP, et al. Inhibition of insulin release from rat pancreatic islets by drugs that are analogues of dopamine. Diabetes 1984; 33: 888-93
70. El Denshary EE, Ismail NA, Gagerman E, et al. Bromocriptine and insulin secretion. Biosci Rep 1982; 2: 115-6
71. Scislowski PW, Tozzo E, Zhang Y, et al. Biochemical mechanisms responsible for the attenuation of diabetic and obese conditions in ob/ob mice treated with dopaminergic agonists. Int J Obes Relat Metab Disord 1999; 23: 425-31
72. Bina KG. Cincotta AH. Dopaminergic agonists normalize elevated hypothalamic neuropeptide Y and corticotropin-releasing hormone, body weight gain, and hyperglycemia in ob/ob mice. Neuroendocrinology 2000; 71: 68-78
73. Erickson JC, Hollopeter G, Palmiter RD. Attenuation of the obesity syndrome of ob/ob mice by the loss of neuropeptide Y. Science 1996; 274: 1704-7
74. Schwartz MW, Woods SC, Porte Jr D, et al. Central nervous system control of food intake. Nature 2000; 404: 661-71
75. Sainsbury A, Rohnerjeanrenau F, Cusin I, et al. Chronic central neuropeptide Y infusion in normal rats: status of the hypothalamo-pituitary-adrenal axis, and vagal mediation of hyperinsulinaemia. Diabetologia 1997; 40: 1269-77
76. Zarjevski N, Cusin I, Vettor R, et al. Chronic intracerebroventricular neuropeptide-Y administration to normal rats mimics hormonal and metabolic changes of obesity. Endocrinology 1993; 133: 1753-8
77. Wasada T, Kawahara R, Iwamoto Y. Lack of evidence for bromocriptine effect on glucose tolerance, insulin resistance, and body fat stores in obese type 2 diabetic patients. Diabetes Care 2000: 23: 1039-40
78. Kamath V. Jones CN, Yip JC, et al. Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women. Diabetes Care 1997; 20: 1697-701
79. Pijl H, Ohashi S. Matsuda M, et al. Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care 2000; 23: 1154-61
80. Meier AH, Cincotta AH, Lovell WC. Timed bromocriptine administration reduces body fat stores in obese subjects and hyperglycemia in type II diabetics. Experientia 1992; 48: 248-53
81. Cincotta AH, Meier AH. Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects. Diabetes Care 1996; 19: 667-70
82. Cincotta AH, Meier AH, Cincotta JM. Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes. Expert Opin Investig Drugs 1999; 8: 1683-707
83. Matthaei S, Stumvoll M, Kellerer M, et al. Pathophysiology and pharmacological treatment of insulin resistance. Endocr Rev 2000; 21: 585-618
84. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 854-65
85. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-53
86. Sowers JR. Dopaminergic control of circadian norepinephrine levels in patients with essential hypertension. J Clin Endocrinol Metab 1981; 53: 1133-7
87. Luchsinger A, Velasco M, Urbina A, et al. Comparative effects of dopaminergic agonists on cardiovascular, renal, and renin-angiotensin systems in hypertensive patients. J Clin Pharmacol 1992; 32: 55-60
88. Kanayama Y. Kohno M, Takaori K, et al. Involvement of sympathetic nervous system inhibition in the hypotensive effect of bromocriptine in spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 1987; 14: 141-4
89. Lahlou S, Duarte GP. Hypotensive action of bromocriptine in the DOCA-salt hypertensive rat: contribution of spinal dopamine receptors. Fundam Clin Pharmacol 1998; 12: 599-606
90. Luchsinger A, Grilli M, Velasco M. Metoclopramide and domperidone block the antihypertensive effect of bromocriptine in hypertensive patients. Am J Ther 1998; 5: 81-8